1-5 of 5
Jaume Pons
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Guillermo Garcia-Manero, Harry P. Erba, Srinivasa R. Sanikommu, Jessica K. Altman, Hamid Sayar, Bart L. Scott, Abraham P. Fong, Shanhong Guan, Feng Jin, Alison J. Forgie, Jaume Pons, Sophia S. Randolph, Michael T. Byrne
Journal: Blood
Blood (2021) 138 (Supplement 1): 2601.
https://doi.org/10.1182/blood-2021-146547
Published: 2021
Journal Articles

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Alison J. Forgie, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MDPhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-135941
Published: 2020
Journal Articles

ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies

Amy Chen, Ons Harrabi, Abraham P Fong, MDPhD, Katherine L. Ruffner, MD, Alison J. Forgie, PhD, Janet Sim, PhD, Sophia S Randolph, MDPhD, Hong Wan, PhD, Jaume Pons, PhD, Tracy C Kuo, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-137112
Published: 2020
Journal Articles

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MD PhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1953.
https://doi.org/10.1182/blood-2019-123219
Published: 2019
Journal Articles

ALX148 Is a High Affinity Sirpα Fusion Protein That Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models

Steven E Kauder, PhD, Tracy C Kuo, PhD, Amy Chen, Ons Harrabi, Sony S Rocha, Laura Doyle, Sangeetha Bollini, Bora Han, PhD, Emma Ruth B Sangalang, Janet Sim, PhD, Sophia Randolph, MDPhD, Jaume Pons, PhD, Hong I Wan, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 112.
https://doi.org/10.1182/blood.V130.Suppl_1.112.112
Published: 2017